The biotech sector has faced a challenging first half of 2025, underperforming relative to the broader tech industry and the S&P 500. Nonetheless, there has been a strong rebound in the second half of 2025, particularly among profitable biotechs, following a significant increase in merger and acquisition (M&A) activity in the XBI index, said Aditya Kotta, head of business development of US and EU at global contract research organisation (CRO) Novotech at a recent conference. Kotta said that the bounce ba ...